Exosomes Vs Breezula (Clascoterone): How They Compare For Hair Loss
Last reviewed on 10 October 2026. We review our treatment guides every six months to keep them accurate.
Key points
They are both new, and they do opposite jobs. Exosome therapy and Breezula (the brand name for clascoterone) are two of the newest options for hair loss, and they work in opposite ways: exosomes stimulate the follicles, while Breezula is designed to block DHT, the hormone that drives male pattern hair loss.
Exosome therapy is a lab-derived injection. Tiny signalling packets, usually grown in a laboratory from stem cells, are injected into the scalp to deliver growth signals to the follicles. It does not touch DHT.
Breezula tackles the cause, locally. Clascoterone is a topical that sits on the follicle’s androgen receptor so DHT cannot bind, acting only at the scalp and aiming to avoid whole-body effects.
Both are unproven, and neither is an approved hair-loss treatment. Exosome therapy is offered in some clinics but is not standardised or approved and its evidence is mostly early, while Breezula, for hair loss, is still in development.
Because they work differently, they are not really rivals. One stimulates growth and the other blocks the hormonal trigger, so in principle they could complement each other rather than compete.
For most people, the proven mainstays come first. Neither of these is an established treatment, so the usual sensible starting point is the proven options, with exosomes and Breezula of interest to watch.
Neither adds hair or restores a bald scalp. Both aim to support the hair you still have; for bald areas a hair transplant is the only option that adds hair. Which suits you is best decided with a clinician.
Exosome therapy and Breezula are two of the newest treatments being talked about for hair loss, which is exactly why people compare them, but they are very different and both are still unproven. Exosome therapy is an in-clinic injection of lab-derived signalling packets that stimulate the follicles. Breezula (clascoterone) is a topical drug that blocks DHT, the hormone behind male pattern hair loss. They work in opposite ways, and crucially neither is yet an approved hair-loss treatment.
This guide compares exosome therapy and Breezula neutrally: what each is, how they differ, how effective they are, where each stands, who each suits, and how they fit with other treatments. It is general information and not a substitute for advice from a doctor.
The short answer
Exosome therapy and Breezula are both new and both unproven, and they approach hair loss in opposite ways. Exosome therapy is an in-clinic procedure: tiny signalling packets, usually grown in a laboratory from stem cells, are injected into the scalp to deliver growth signals to tired follicles. It does nothing about DHT, the hormone that drives male pattern loss, and its evidence is mostly laboratory work with only early data in people; it is not standardised or approved, and it is expensive. Breezula is the brand name for clascoterone, a topical anti-androgen that sits on the follicle’s androgen receptor and blocks DHT from acting there, tackling the hormonal cause locally; for hair loss it too is still in development and not approved. Because one stimulates growth and the other blocks the trigger, they are not really competitors, and in principle could be used together. But the honest point is that neither is an established treatment, so for most people the sensible starting point is the proven mainstays, with exosomes and Breezula of interest to watch. Neither, in any case, can regrow a scalp that is already bald.
What is exosome therapy?
Exosomes are tiny signalling packets that cells use to send messages to one another. In hair treatments they are usually grown in a laboratory from stem cells and then injected into the scalp to deliver those signals to the follicles. As a review of exosomes in hair loss describes, they are "nanosized extracellular vesicles rich in proteins, nucleic acids, and lipids", and the idea is that these contents stimulate tired follicles. The evidence, though, is early: a systematic review of exosome treatment in hair restoration found "no significant adverse reactions associated with exosome treatment...reported thus far", but was clear that "although current clinical evidence supporting the use of exosome treatment is limited, there is a growing body of evidence suggesting its therapeutic potential". In practice it is a newer, in-clinic treatment that is not standardised or approved and is expensive, and like the other stimulating treatments it does nothing to DHT. Our guide on exosome therapy for hair loss covers it in detail, and finasteride versus exosomes compares it with the first-line DHT-lowering tablet.
What is Breezula (clascoterone)?
Breezula is the brand name under development for clascoterone used on the scalp for hair loss. Unlike exosome therapy, it works directly against DHT. As a narrative review of clascoterone explains, "clascoterone cream is the first topical androgen receptor inhibitor approved by the U.S. Food and Drug Administration (FDA) for the treatment of acne vulgaris", and it works "by binding to androgen receptors in a manner competitive with DHT", blocking the signalling that DHT would otherwise trigger at the follicle. Crucially, "topical administration of clascoterone enables selective targeting of cutaneous androgen receptors, while its rapid metabolic inactivation to cortexolone, an inactive metabolite, minimizes the potential for systemic adverse effects", which is the appeal of a scalp anti-androgen: to tackle the hormonal cause locally while avoiding whole-body effects. For hair loss specifically it is not yet approved; our guide on Breezula (clascoterone) for hair loss covers where it stands.
Which is more effective for hair loss?
Neither has strong, settled evidence, and they are not directly comparable because they do different jobs and are both still emerging. Exosome therapy is promising in theory, but as the systematic review makes clear its clinical evidence is limited and it is not standardised or approved. Clascoterone for hair loss is also promising but early: the clascoterone review notes it "has emerged as a promising candidate for the treatment of androgenetic alopecia", while being clear that "emerging but still incomplete data suggest potential applications in androgenetic alopecia", and that "in phase 2 studies, clascoterone treatment showed favorable outcomes in measures such as scalp sebometric measurement, hair diameter, follicular density, and pull test/wash test".
And the later-stage hair-loss trials for clascoterone have not yet been independently published. The review notes that the pivotal phase 3 AGA programme "was reported to be completed in 2025", but that "the complete results of these trials have not been published in peer-reviewed journals and are available only through sponsor-issued announcements", and that "because these findings have not undergone independent scientific evaluation, they cannot be presented as established evidence". So the honest position is that both are promising but unproven: exosome therapy is available in some clinics but not standardised or approved, while Breezula is not yet available for hair loss at all. Each tackles a different part of the problem.
Exosomes vs Breezula: how do they compare?
They are both new and unproven, target opposite things, and differ in form and availability:
What they are: exosome therapy is an in-clinic injection of lab-derived signalling packets; Breezula (clascoterone) is a topical anti-androgen you would apply to the scalp.
How they work: exosomes stimulate the follicles by delivering growth signals, without affecting DHT; clascoterone blocks DHT from binding the follicle’s androgen receptor, so it tackles the hormonal cause rather than stimulating growth.
What they tackle: exosomes support hair regardless of the cause but do not slow the underlying process; clascoterone targets that underlying process locally but does not itself stimulate new growth.
Availability: exosome therapy is offered in some clinics now, but it is not standardised or approved; clascoterone is approved only as an acne cream, and the hair-loss version is still in development, not yet approved.
Effort and cost: exosome therapy means in-clinic injections and tends to be expensive; Breezula, if approved, would be a topical applied at home.
Evidence: both are promising but early. Exosome therapy is backed mostly by laboratory work with only limited clinical data; clascoterone for hair loss has promising but incomplete data, with the key late-stage results not yet peer-reviewed.
Rivals or partners: because one stimulates growth and the other would block the hormonal trigger, they are complementary rather than competing, and could in principle be used together.
What neither does: neither adds new hair or restores a bald area, so both are for supporting the hair you still have rather than replacing hair that is gone.
Which is right for you?
The honest answer is that, for most people, neither is the place to start, because neither is a proven, approved hair-loss treatment. Exosome therapy is available in some clinics, so it is something you could have now, but it is expensive, not standardised, and backed mostly by laboratory evidence, which makes it an experimental choice rather than an established one. Breezula is not currently available for hair loss at all, so it is not a choice you can make right now, however appealing a scalp anti-androgen that tackles the hormonal cause locally might sound. Clascoterone is the most advanced treatment of that kind, so it is well worth watching, but it too remains promising rather than proven. The more useful way to think about them is as two different, still-emerging jobs: exosomes stimulate growth, while a treatment like Breezula would protect hair from DHT, and in time some people may benefit from both, usually on top of the proven mainstays rather than instead of them.
Neither, in any case, suits someone whose loss is advanced or whose follicles are already gone, because both only aim to support hair that is still there. Because both are experimental for hair loss, the sensible step is to discuss your options with a clinician, who can set out what is proven and available now and keep you informed as newer treatments reach approval.
Can they be combined with other treatments?
For now, combining exosome therapy and Breezula is largely theoretical, because Breezula is not yet available for hair loss and both are still emerging. In principle it is a logical pairing, because exosomes stimulate growth while clascoterone would block the hormonal trigger, so the two attack the problem at different points. In practice, the better-evidenced approach today is to start with the proven mainstays rather than two experimental treatments: the drug that tackles the cause is a DHT-lowering tablet such as finasteride, compared with exosomes in our guide on finasteride versus exosomes, and the other anti-androgen comparisons are covered in our guides on finasteride versus Breezula, dutasteride versus Breezula and minoxidil versus Breezula.
Neither exosome therapy nor Breezula can restore hair that is already gone. Where loss is more advanced, a hair transplant is a separate option that redistributes your own permanent hair, and stimulating treatments are sometimes used around a transplant to support the surrounding hair. The key point is that these are treatments intended to support the hair you have, used as part of a wider plan, not a cure.
The bottom line
Exosome therapy and Breezula are two of the newest options for hair loss, and they tackle it in opposite ways. Exosome therapy is an in-clinic injection of lab-derived signalling packets that stimulate the follicles, without touching DHT, while Breezula (clascoterone) is a topical anti-androgen that blocks DHT, the hormone behind male pattern hair loss, at the scalp. Both are promising but unproven: exosome therapy is offered in some clinics but is not standardised or approved and is expensive, while Breezula is still in development and not approved for hair loss at all. Neither adds hair or restores a bald area.
If you are weighing them today, the honest answer is that neither is a proven starting point, so for most people the sensible route is the established mainstays first, with exosomes and Breezula of interest to watch. The two are not really rivals: exosomes stimulate growth, and a treatment like Breezula would protect hair from DHT, so some people may eventually benefit from both. A clinician can help you decide what suits your hair loss now, and how newer treatments might fit in once they are approved.
Frequently asked questions
Is Breezula better than exosome therapy for hair loss?
It is not really the right question, because both are still unproven and they do different jobs. Exosome therapy stimulates the follicles with lab-derived signalling packets, while Breezula blocks DHT, the hormone that drives the loss. Exosome therapy is available in some clinics but is not standardised or approved and its evidence is mostly early; clascoterone, the drug in Breezula, is a promising topical anti-androgen whose hair-loss data are still incomplete and whose key late-stage results have not yet been peer-reviewed. So neither is an established treatment, and the two may ultimately work together rather than as alternatives, usually on top of the proven mainstays.
Is Breezula available for hair loss?
Not yet. Clascoterone, the active drug, is approved as a cream for acne, but the higher-strength scalp solution developed for hair loss, Breezula, is still in clinical development and has not been approved for hair loss in the UK or elsewhere. Later-stage trials have been reported by the company, but the full results have not yet been published in peer-reviewed journals, and an approval decision has not been made. Exosome therapy, by contrast, is offered in some clinics now, though it too is not an approved or standardised hair-loss treatment.
What is the difference between exosome therapy and Breezula?
They work in opposite ways. Exosome therapy is an in-clinic procedure: tiny signalling packets, usually grown in a laboratory from stem cells, are injected into the scalp to stimulate the follicles. It does not affect DHT, the hormone behind male pattern loss. Breezula (clascoterone) is a topical anti-androgen: it sits on the follicle’s androgen receptor and blocks DHT from acting there, tackling the hormonal cause locally. So exosomes stimulate growth, while Breezula would protect hair from the hormone; and exosome therapy is offered in some clinics now, while Breezula is still in development as a topical.
Are exosomes or Breezula approved for hair loss?
Neither is approved as a hair-loss treatment. Exosome products for hair loss are not standardised or approved, and regulators have raised concerns about unapproved exosome treatments, even though some clinics offer them. Breezula, the scalp form of clascoterone, is still in clinical development for hair loss and has not been approved. Clascoterone is approved only in its lower-strength cream form for acne. So both should be understood as experimental for hair loss, which is why proven, approved options are the usual first choice.
Get back to Great Hair
in 3 Easy Steps:
01
Arrange Free Consultation
Speak to one of our specialist consultants for expert advice on our range of different hair loss treatments
02
Book Your Procedure
Place a deposit to reserve a time slot at one of the My Hair UK clinics across the UK
03
Attend Your Surgery
Arrive on the day and our specialist surgical team will look after your every need
What People Say About Us
Read our independent My Hair UK Reviews on Reviews.io
The Surgical Team
The surgical team is what makes the difference on the day. The clinics’ five surgeons are all GMC-registered, with a minimum of 1,000 FUE hair transplant procedures each to their name. Between them the team handles complex cases, including Afro-textured and women’s hair transplants, hairline design and lowering, and revision work.
Manchester clinic
• Dr Khawaja Masood Munir: GMC 6122581.
8+ years’ experience, 1,400+ hair transplant surgeries.
• Dr Haider Gillani: GMC 8030796.
1,000+ procedures, with specific expertise in complex cases requiring detailed anatomical understanding.
London (Harrow) clinic
• Dr Mahdi Alosert: GMC 6168297.
20+ years’ clinical experience. Specialist in Afro-Caribbean hair and hairline lowering.
• Dr Shuaib Mir: GMC 7567898.
1,200+ hair transplant cases. BAAPS plastic surgery and RCS anatomy training.
• Dr Zakar Rafiq: GMC 6164032.
MBBS and BSc (Hons) from Imperial College London. Associate Member of the International Society of Hair Restoration Surgery (ISHRS).
You can meet the surgeon who will perform your procedure at your free consultation.